Notably, hepatocyte‐specific knockdown of Rubicon has been shown to improve liver steatosis in NAFLD mice, indicating that Rubicon may be a potential therapeutic target for NAFLD.[20] In this study, a single‐dose‐usage lipid nanoparticle was developed for NAFLD treatment, designed to deliver CRISPR‐Cas9 components against Rubicon. This evidence concerns the gene RUBCN and fatty liver disease.